Article
Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
The oncologist - 1 Mar 2020
Fang Wenfeng, Zhao Shen, Liang Ying, Yang Yunpeng, Yang Lin, Dong Xiaorong, Zhang Li, Tang Yong, Wang Shoufeng, Yang Yang, Ma Xiaoyan, Wang Minghui, Wang Wenjing, Zhao Songhui, Wang Kai, Gao Song, Zhang Li
Abstract excerpt
BACKGROUND: Human epidermal growth factor receptor 2 (HER2)-mutant lung cancer remains an orphan of specific targeted therapy. The variable responses to anti-HER2 therapies in these patients prompt us to examine impact of HER2 variants and co-mutations on responses to anti-HER2 treatments in lung cancer. PATIENTS AND METHODS: Patients with stage IV/recurrent HER2-mutant lung cancers identified through...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.